The relationship between plasminogen activator inhibitor-1 levels and the course of disease in COVID-19 patients

Avcı, Burak Yasin; cinar, ayse surhan; Baltan Avcı, Ecem; Serin, Erdinc; Kibar Akilli, Isil

doi:10.1515/tjb-2022-0044

The relationship between plasminogen activator inhibitor-1 levels and the course of disease in COVID-19 patients

Ecem BALTAN, (Tıbbi Biyokimya, İstanbul Şişli Hamidiye Etfal Eğitim ve Araştırma Hastanesi, Şişli, 34360, Türkiye)

Erdinç SERİN, (Tıbbi Biyokimya, İstanbul Şişli Hamidiye Etfal Eğitim ve Araştırma Hastanesi, Şişli, Türkiye,)

Burak Yasin AVCI, (Amasya Üniversitesi, Amasya, Turkey,)

Isil Kibar Akilli, (Göğüs Hastalıkları Bölümü, İstanbul Şişli Hamidiye Etfal Eğitim ve Araştırma Hastanesi, Şişli, Türkiye,)

Ayşe SURHAN ÇINAR (Anesteziyoloji ve Reanimasyon Bölümü, İstanbul Şişli Hamidiye Etfal Eğitim ve Araştırma Hastanesi, Şişli, Türkiye)

Türk Biyokimya Dergisi

7 1

Yıl: 2022 Cilt: 47 Sayı: 5 Sayfa Aralığı: 672 - 679 Metin Dili: İngilizce DOI: 10.1515/tjb-2022-0044 İndeks Tarihi: 08-05-2023

The relationship between plasminogen activator inhibitor-1 levels and the course of disease in COVID-19 patients

Öz:

Objectives: Studies have shown that fibrinolysis activity is insufficient in COVID-19 patients. Plasminogen activator inhibitor-1 (PAI-1) is an important antifibrinolytic molecule that plays a key role in the fibrinolytic system. In our study; we aimed to evaluate serum PAI-1 and other biochemical parameters of COVID-19 patients in terms of disease course and mortality. Methods: A total of 40COVID-19 patients were hospitalized in the service and intensive care unit (ICU) of our hospital from October to December 2020 and 20 healthy volunteers were included in our study. The patients were grouped as those who transferred to the ICU from the service and transferred to service from the ICU. The first and second values of the same patients in both the service and the ICU were analyzed by SPSS. Results: The PAI-1 levels of the patients in the ICU were significantly higher than the levels of the same patients in the service and the healthy control group (p<0.001). IL-6, ferritin, and D-dimer levels in the ICU of the same patients were significantly higher than the levels of service and healthy control group (p<0.001). A positive correlation was found between initial serum PAI-1 and D-dimer levels in patients hospitalized in the service (p=0.039) and initial serum ferritin and IL-6 levels in the ICU (p=0.031). Conclusions: In our study, we found that PAI-1 levels increased significantly with the increase in mortality in COVID-19 patients.

Anahtar Kelime:

Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık

1. WHO. COVID-19 weekly epidemiological update, 2022. Available from: https://www.who.int/docs/default-source/coronaviruse/ situation-reports/20220817_weekly_epi_update_105.pdf? sfvrsn=cfeb4c18_3&download=true.
2. McGonagle D, Sharif K, O’Regan A, Bridgewood C. Interleukin-6 use in COVID-19 pneumonia related macrophage activation syndrome. Autoimmun Rev 2020;19:102537.
3. Dosquet C, Weill D, Wautier JL. Cytokines and thrombosis. J Cardiovasc Pharmacol 1995;25:S13–9.
4. Thachil J, Agarwal S. Understanding the COVID-19 coagulopathy spectrum. Anaesthesia 2020;75:1432–6.
5. Grau GE, de Moerloose P, Bulla O, Lou J, Lei Z, Reber G, et al. Haemostatic properties of human pulmonary and cerebral microvascular endothelial cells. Thromb Haemostasis 1997;77: 585–90.
6. MacLaren R, Stringer KA. Emerging role of anticoagulants and fibrinolytics in the treatment of acute respiratory distress syndrome. Pharmacotherapy 2007;27:860–73.
7. Panigada M, Tagliabue P, Grasselli G, Novembrino C, Chantarangkul V, Pesenti A, et al. Hypercoagulability of COVID-19 patients in the intensive care unit. A report of thromboelastography findings and other parameters of hemostasis. J Thromb Haemostasis 2020;18:1738–42.
8. Yang X, Yu Y, Xu J, Shu H, Xia J, Liu H, et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet Respir Med 2020;8:475–81.
9. Blasi F, Carmeliet P. uPAR: a versatile signalling orchestrator. Nat Rev Mol Cell Biol 2002;3:932–43.
10. Bhimraj A, Morgan RL, Shumaker AH, Lavergne V, Baden L, Chi-Chung Cheng V, et al. Infectious diseases society of America guidelines on the treatment and management of patients with COVID-19. Infectious Diseases Society of America; 2021. Version 4.3.0. Available from: https://www.idsociety.org/practiceguideline/ covid-19-guideline-treatment-and-management/.
11. Kruithof EK. Regulation of plasminogen activator inhibitor type 1 gene expression by inflammatory mediators and statins. Thromb Haemostasis 2008;100:969–75.
12. Nougier C, Benoit R, Simon M, Desmurs-Clavel H, Marcotte G, Argaud L, et al. Hypofibrinolytic state and high thrombin generation may play a major role in SARS-COV2 associated thrombosis. J Thromb Haemostasis 2020;18:2215–9.
13. Umemura Y, Yamakawa K, Kiguchi T, Nishida T, Kawada M, Fujimi S. Hematological phenotype of COVID-19-induced coagulopathy: far from typical sepsis-induced coagulopathy. J Clin Med 2020;9:75.
14. TianS,Hu W, Niu L, LiuH, Xu H, XiaoSY. Pulmonary pathology of early phase 2019 novel coronavirus (COVID-19) pneumonia in two patients with lung cancer. J Thorac Oncol 2020;15:700–4.
15. Luo WR, Yu H, Gou JZ, Li XX, Sun Y, Li JX, et al. Histopathologic findings in the explant lungs of a patient with COVID-19 treated with bilateral orthotopic lung transplant. Transplantation 2020; 104:e329–31.
16. Takahashi K, Uwabe Y, Sawasaki Y, Kiguchi T, Nakamura H, Kashiwabara K, et al. Increased secretion of urokinase-type plasminogen activator by human lung microvascular endothelial cells. Am J Physiol 1998;275:L47–54.
17. Ware LB, Matthay MA, Parsons PE, Thompson BT, Januzzi JL, Eisner MD. Pathogenetic and prognostic significance of altered coagulation and fibrinolysis in acute lung injury/acute respiratory distress syndrome. Crit Care Med 2007;35:1821–8.
18. Groeneveld AB, Thijs LG. Increased systemic microvascular permeability in septic shock. Prog Clin Biol Res 1987;236A:487–94.
19. Gralinski LE, Iii AB, Jeng S. Mechanisms of severe acute respiratory syndrome coronavirus. MBio 2013;4:1–12.
20. Wu YP, Wei R, Liu ZH, Chen B, Lisman T, Ren DL, et al. Analysis of thrombotic factors in severe acute respiratory syndrome (SARS) patients. Thromb Haemostasis 2006;96:100–1.
21. Wang J, Hajizadeh N, Moore EE, McIntyre RC, Moore PK, Veress LA, et al. Tissue plasminogen activator (tPA) treatment for COVID-19 associated acute respiratory distress syndrome (ARDS): a case series. J Thromb Haemostasis 2020;18:1752–5.
22. Glas GJ, Van Der Sluijs KF, Schultz MJ, Hofstra JJ, Van Der Poll T, Levi M. Bronchoalveolar hemostasis in lung injury and acute respiratory distress syndrome. J Thromb Haemostasis 2013;11:17–25.
23. Ye Q, Wang B, Mao J. The pathogenesis and treatment of the ‘Cytokine Storm’’ in COVID-19. J Infect 2020;80:607–13.
24. Recalcati S, Invernizzi P, Arosio P, Cairo G. New functions for an iron storage protein: the role of ferritin in immunity and autoimmunity. J Autoimmun 2008;30:84–9.
25. Dolhnikoff M, Duarte-Neto AN, de Almeida Monteiro RA, Ferraz da Silva LF, de Oliveira EP, Nascimento Saldiva PH, et al. Pathological evidence of pulmonary thrombotic phenomena in severe COVID-19. J Thromb Haemostasis 2020;18:1517–9.
26. Ruan Q, Yang K, Wang W, Jiang L, Song J. Clinical predictors of mortality due to COVID -19 based on analysis of data of 150 patients from Wuhan, China. Intensive Care Med 2020;46: 846–8.
27. Ranucci M, Ballotta A, Di Dedda U, Baryshnikova E, Dei Poli M, Resta M, et al. The procoagulant pattern if patients with COVID -19 acute respiratory distress syndrome. J Thromb Haemostasis 2020;18:1747–51.
28. Zhang P, Shi L, Xu J, Wang Y, Yang H. Elevated interleukin-6 and adverse outcomes in COVID-19 patients: a meta-analysis based on adjusted effect estimates. Immunogenetics 2020;72: 431–7.
29. Cheng L, Li H, Li L, Liu C, Yan S, Chen H, et al. Ferritin in the coronavirus disease 2019 (COVID-19): a systematic review and meta-analysis. J Clin Lab Anal 2020;34:1–18.
30. Yağcı S, Serin E, Acicbe Ö, ZerenMİ, Odabaşı MS. The relationship between serum erythropoietin, hepcidin, and haptoglobin levels with disease severity and other biochemical values in patients with COVID-19. Int J Lab Hematol 2021;43:142–51.
31. Shah S, Shah K, Patel SB, Patel FS, Osman M, Velagapudi P, et al. Elevated D-dimer levels are associated with increased risk of mortality in coronavirus disease 2019: a systematic review and meta-analysis. Cardiol Rev 2020;28:295–2.
32. Kang S, Tanaka T, Inoue H, Ono C, Hashimoto S, Kioi Y, et al. IL-6 trans-signaling induces plasminogen activator inhibitor-1 from vascular endothelial cells in cytokine release syndrome. Proc Natl Acad Sci U S A 2020;117:22351–6.
33. Nagata K, Shomoda K. Myeloproliferative diseases caused by JAK2 mutation. Rinsho Byori 2009;57:357–64.
34. Frank DA. STAT3 as a central mediator of neoplastic cellular transformation. Cancer Lett 2007;251:199–10.
35. Matsuyama T, Kubli SP, Yoshinaga SK, Pfeffer K, Mak TW. An aberrant STAT pathway is central to COVID-19. Cell Death Differ 2020;27:3209–25.

APA	Baltan Avcı E, Serin E, Avcı B, Kibar Akilli I, cinar a (2022). The relationship between plasminogen activator inhibitor-1 levels and the course of disease in COVID-19 patients. , 672 - 679. 10.1515/tjb-2022-0044
Chicago	Baltan Avcı Ecem,Serin Erdinc,Avcı Burak Yasin,Kibar Akilli Isil,cinar ayse surhan The relationship between plasminogen activator inhibitor-1 levels and the course of disease in COVID-19 patients. (2022): 672 - 679. 10.1515/tjb-2022-0044
MLA	Baltan Avcı Ecem,Serin Erdinc,Avcı Burak Yasin,Kibar Akilli Isil,cinar ayse surhan The relationship between plasminogen activator inhibitor-1 levels and the course of disease in COVID-19 patients. , 2022, ss.672 - 679. 10.1515/tjb-2022-0044
AMA	Baltan Avcı E,Serin E,Avcı B,Kibar Akilli I,cinar a The relationship between plasminogen activator inhibitor-1 levels and the course of disease in COVID-19 patients. . 2022; 672 - 679. 10.1515/tjb-2022-0044
Vancouver	Baltan Avcı E,Serin E,Avcı B,Kibar Akilli I,cinar a The relationship between plasminogen activator inhibitor-1 levels and the course of disease in COVID-19 patients. . 2022; 672 - 679. 10.1515/tjb-2022-0044
IEEE	Baltan Avcı E,Serin E,Avcı B,Kibar Akilli I,cinar a "The relationship between plasminogen activator inhibitor-1 levels and the course of disease in COVID-19 patients." , ss.672 - 679, 2022. 10.1515/tjb-2022-0044
ISNAD	Baltan Avcı, Ecem vd. "The relationship between plasminogen activator inhibitor-1 levels and the course of disease in COVID-19 patients". (2022), 672-679. https://doi.org/10.1515/tjb-2022-0044

APA	Baltan Avcı E, Serin E, Avcı B, Kibar Akilli I, cinar a (2022). The relationship between plasminogen activator inhibitor-1 levels and the course of disease in COVID-19 patients. Türk Biyokimya Dergisi, 47(5), 672 - 679. 10.1515/tjb-2022-0044
Chicago	Baltan Avcı Ecem,Serin Erdinc,Avcı Burak Yasin,Kibar Akilli Isil,cinar ayse surhan The relationship between plasminogen activator inhibitor-1 levels and the course of disease in COVID-19 patients. Türk Biyokimya Dergisi 47, no.5 (2022): 672 - 679. 10.1515/tjb-2022-0044
MLA	Baltan Avcı Ecem,Serin Erdinc,Avcı Burak Yasin,Kibar Akilli Isil,cinar ayse surhan The relationship between plasminogen activator inhibitor-1 levels and the course of disease in COVID-19 patients. Türk Biyokimya Dergisi, vol.47, no.5, 2022, ss.672 - 679. 10.1515/tjb-2022-0044
AMA	Baltan Avcı E,Serin E,Avcı B,Kibar Akilli I,cinar a The relationship between plasminogen activator inhibitor-1 levels and the course of disease in COVID-19 patients. Türk Biyokimya Dergisi. 2022; 47(5): 672 - 679. 10.1515/tjb-2022-0044
Vancouver	Baltan Avcı E,Serin E,Avcı B,Kibar Akilli I,cinar a The relationship between plasminogen activator inhibitor-1 levels and the course of disease in COVID-19 patients. Türk Biyokimya Dergisi. 2022; 47(5): 672 - 679. 10.1515/tjb-2022-0044
IEEE	Baltan Avcı E,Serin E,Avcı B,Kibar Akilli I,cinar a "The relationship between plasminogen activator inhibitor-1 levels and the course of disease in COVID-19 patients." Türk Biyokimya Dergisi, 47, ss.672 - 679, 2022. 10.1515/tjb-2022-0044
ISNAD	Baltan Avcı, Ecem vd. "The relationship between plasminogen activator inhibitor-1 levels and the course of disease in COVID-19 patients". Türk Biyokimya Dergisi 47/5 (2022), 672-679. https://doi.org/10.1515/tjb-2022-0044